Abstract 440P
Background
Targeted therapy is emerging as the frontline of cancer treatment due to improved clinical outcomes and enhanced quality of life among cancer patients. However, treatments related to adverse events (AEs) of targeted therapy are associated with the outcome of cancer treatments. This study investigated the frequency and severity of adverse events in cancer patients who receive targeted therapy.
Methods
The study was conducted at a university hospital in northern Thailand, from January to June 2023. We performed a retrospective study concerning patients treated with targeted therapy including multikinase inhibitors, epidermal-growth factors (EGFR) inhibitors, anaplastic lymphoma kinase (ALK) inhibitors, cyclin-dependent kinases 4 and 6 (CDK4/6), immune checkpoint inhibitors (ICIs), mammalian target of rapamycin (mTOR) inhibitors, and phosphoinositide 3-kinases (PI3Ks) inhibitors. All adverse events were reported by pharmacists and confirmed by medical oncologists in electronic medical record (EMR) based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Descriptive statistics were applied for reporting frequency of AEs.
Results
There are 136 cancer patients with targeted therapy. The majority of patients were female (58.1%) with mean age 64.0 ± 11.9 years old. Non-small cell lung cancer is the most common cancer (47.1%) followed by hepatocellular carcinoma (14.7%) and breast cancer (11%). The frequency of targeted therapy treatment was erlotinib (18.4%), ceritinib (18.4%), regorafenib (10.3%) and ribociclib (8.1%). Eighty-two patients (60.3%) reported AEs. The most AEs were grade 1-2 (64%). Skin rash was the most common AE (22.8%), subsequently with dry skin (16.9%) and diarrhea (14.7%). Six patients (4.4%) had grade 3 AEs including skin rash (0.7%), Hand foot skin reaction (0.7%), transaminitis (1.5%), and neutropenia (1.5%).
Conclusions
This study demonstrated the frequency of AEs among cancer patients with targeted therapy, the most common AEs included dermatological problems. Rarely severe AEs were reported. Health care providers will need to educate and monitor cancer patients to prevent and monuments AEs during targeted therapy treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
452P - The relationship between BCG immunotherapy and oxidative stress parameters in patients with non-muscle invasive bladder cancer
Presenter: Mukul Singh
Session: Poster Display
Resources:
Abstract
453P - Palonosetron plus megestrol acetate verses palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: A randomized, multicenter, crossover, phase II trial
Presenter: Qiaoqi Li
Session: Poster Display
Resources:
Abstract
454P - A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Presenter: Akira Ooki
Session: Poster Display
Resources:
Abstract
455P - Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period
Presenter: Matti Aapro
Session: Poster Display
Resources:
Abstract
456P - Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
457P - Anticoagulation for terminal cancer patients with cancer associated venous thromboembolism
Presenter: Sang Bo Oh
Session: Poster Display
Resources:
Abstract
458P - Association between TSPAN15 and SLC44A2 genetic polymorphisms and venous thromboembolism in cancer patients
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
459P - Association between national health screening program and undertreatment of dyslipidemia in cancer survivors: A cross-sectional study
Presenter: Sujeong Shin
Session: Poster Display
Resources:
Abstract
460P - Group to grow: A systematic review of group-based interventions for post-traumatic growth on cancer patients
Presenter: Dyta William
Session: Poster Display
Resources:
Abstract
461P - A randomized controlled trial of yoga in locally advanced non-small cell lung cancer patients receiving chemoradiotherapy
Presenter: Indranil Khan
Session: Poster Display
Resources:
Abstract